Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study. (Q42279735)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

1 reference

tenofovir/emtricitabine

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Adrian Curran

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Eugènia Negredo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Vicente Estrada

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Federico Pulido

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Bonaventura Clotet Sala

5

object named as

B Clotet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

M Larrousse

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

J Sanz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

J Berenguer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

R Rubio

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

P Ferrer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

M L Alvarez

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

S Arterburn

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

E Martínez

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

9 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

327-336

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 February 2020

cites work

1 reference

Adherence to HAART Regimens

21 January 2018

1 reference

Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy

21 January 2018

1 reference

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

21 January 2018

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

How much fat loss is needed for lipoatrophy to become clinically evident?

21 January 2018

1 reference

Human immunodeficiency virus atropy induces modification of subcutaneous adipose tissue architecture: in vivo visualization by high-resolution magnetic resonance imaging

21 January 2018

1 reference

Fat distribution in men with HIV infection

21 January 2018

1 reference

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

21 January 2018

1 reference

Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry

21 January 2018

1 reference

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

21 January 2018

1 reference

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

21 January 2018

1 reference

Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

21 January 2018

1 reference

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study

21 January 2018

1 reference

Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis

21 January 2018

1 reference

Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study

21 January 2018

1 reference

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

21 January 2018

1 reference

A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy

21 January 2018

1 reference

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

21 January 2018

1 reference

A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.

21 January 2018

1 reference

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

21 January 2018

1 reference

Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine

21 January 2018

1 reference

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients

21 January 2018

1 reference

Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat.

21 January 2018

1 reference

Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.

21 January 2018

1 reference

Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy

21 January 2018

1 reference

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/HIV.12011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23298339%20AND%20SRC:MED&resulttype=core&format=json